CN101437512A - 葡萄糖激酶活化剂 - Google Patents

葡萄糖激酶活化剂 Download PDF

Info

Publication number
CN101437512A
CN101437512A CNA2007800107261A CN200780010726A CN101437512A CN 101437512 A CN101437512 A CN 101437512A CN A2007800107261 A CNA2007800107261 A CN A2007800107261A CN 200780010726 A CN200780010726 A CN 200780010726A CN 101437512 A CN101437512 A CN 101437512A
Authority
CN
China
Prior art keywords
alkyl
heteroaryl
saturated
aryl
partially unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800107261A
Other languages
English (en)
Chinese (zh)
Inventor
T·D·艾彻尔
S·A·博伊德
M·J·奇卡雷利
K·R·孔德罗斯基
R·J·欣克林
A·辛格
T·M·特纳
F·G·拉斯塔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN101437512A publication Critical patent/CN101437512A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNA2007800107261A 2006-01-27 2007-01-24 葡萄糖激酶活化剂 Pending CN101437512A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76317306P 2006-01-27 2006-01-27
US60/763,173 2006-01-27

Publications (1)

Publication Number Publication Date
CN101437512A true CN101437512A (zh) 2009-05-20

Family

ID=38109991

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800107261A Pending CN101437512A (zh) 2006-01-27 2007-01-24 葡萄糖激酶活化剂

Country Status (9)

Country Link
US (1) US8022222B2 (enExample)
EP (1) EP1986645B1 (enExample)
JP (1) JP5236499B2 (enExample)
CN (1) CN101437512A (enExample)
AT (1) ATE539748T1 (enExample)
CA (1) CA2637172A1 (enExample)
ES (1) ES2378704T3 (enExample)
TW (1) TW200740804A (enExample)
WO (1) WO2007089512A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786517A (zh) * 2011-05-18 2012-11-21 中国医学科学院药物研究所 Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
CN108864151A (zh) * 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
CN110898049A (zh) * 2019-11-29 2020-03-24 华中师范大学 二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂
CN113993859A (zh) * 2019-06-25 2022-01-28 益方生物科技(上海)股份有限公司 杂环化合物、其制备方法及其使用方法
CN115448916A (zh) * 2016-10-14 2022-12-09 林伯士拉克许米公司 Tyk2抑制剂及其用途

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091770A1 (en) * 2007-01-24 2008-07-31 Array Biopharma Inc. 2-aminopyridine derivatives as glucokinase activators
US8362037B2 (en) * 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
WO2009022179A2 (en) * 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
WO2010058846A1 (ja) 2008-11-21 2010-05-27 アステラス製薬株式会社 ４，６-ジアミノニコチンアミド化合物
AU2009326148B2 (en) 2008-12-11 2014-05-08 Respivert Limited p38 MAP kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
JP5787977B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012121314A1 (ja) 2011-03-09 2012-09-13 第一三共株式会社 ジピリジルアミン誘導体
JP5748210B2 (ja) * 2011-05-26 2015-07-15 日本化薬株式会社 複素環化合物の製造方法
SG10201604682VA (en) * 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US9133174B2 (en) 2011-09-05 2015-09-15 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201329067A (zh) * 2011-12-08 2013-07-16 Amgen Inc 作為ｇｋａ活化劑之脲化合物
WO2013173672A1 (en) 2012-05-18 2013-11-21 Array Biopharma Inc. Method for the preparation of thiadiazoles
WO2014074657A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
WO2014159938A1 (en) * 2013-03-13 2014-10-02 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
CN106749002A (zh) * 2015-02-12 2017-05-31 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
JP6483272B2 (ja) * 2015-02-17 2019-03-13 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ 白色脂肪組織の褐色化を誘導するための化合物および方法
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
JP2018515597A (ja) * 2015-04-07 2018-06-14 イーエルエイ ファーマ リミテッドＥｌａ Ｐｈａｒｍａ Ｌｔｄ カテプシンｃおよび／またはｃｅｌａ１および／またはｃｅｌａ３ａおよび／またはそれらに構造的に関連する酵素を特異的に標的とする細胞および／または組織壊死の処置および／または防止のための組成物
US10759739B2 (en) * 2015-06-11 2020-09-01 University of Pittsburgh—of the Commonwealth System of Higher Education P62-ZZ small molecule modulators
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US11753403B2 (en) 2020-03-03 2023-09-12 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2022147694A1 (en) * 2021-01-06 2022-07-14 Beijing Erai Therapeutics Co., Ltd. Aminoheteroaryl compounds and uses thereof
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384101A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1404672B1 (en) * 2001-06-22 2006-01-18 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60314603T2 (de) 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
US20040023978A1 (en) * 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
JP2006509774A (ja) * 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
WO2004041164A2 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
AU2005264213A1 (en) * 2004-05-21 2006-01-26 Msd K.K. Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton
NZ556433A (en) * 2005-01-14 2010-10-29 Cgi Pharmaceuticals Inc 1, 3-diaryl substituted ureas as modulators of kinase activity
US20090105250A1 (en) * 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864151A (zh) * 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
CN102786517A (zh) * 2011-05-18 2012-11-21 中国医学科学院药物研究所 Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
CN102786517B (zh) * 2011-05-18 2017-06-06 中国医学科学院药物研究所 Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
CN115448916A (zh) * 2016-10-14 2022-12-09 林伯士拉克许米公司 Tyk2抑制剂及其用途
CN113993859A (zh) * 2019-06-25 2022-01-28 益方生物科技(上海)股份有限公司 杂环化合物、其制备方法及其使用方法
CN110898049A (zh) * 2019-11-29 2020-03-24 华中师范大学 二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂
CN110898049B (zh) * 2019-11-29 2021-09-14 华中师范大学 二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂

Also Published As

Publication number Publication date
ATE539748T1 (de) 2012-01-15
JP5236499B2 (ja) 2013-07-17
CA2637172A1 (en) 2007-08-09
EP1986645A1 (en) 2008-11-05
JP2009524670A (ja) 2009-07-02
TW200740804A (en) 2007-11-01
ES2378704T3 (es) 2012-04-17
US20090247526A1 (en) 2009-10-01
US8022222B2 (en) 2011-09-20
WO2007089512A1 (en) 2007-08-09
EP1986645B1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
CN101437512A (zh) 葡萄糖激酶活化剂
KR100904938B1 (ko) Ｖｅｇｆ－ｒ２ 억제제로서의 이미다조(１,２―ａ)피리딘화합물
EP2683710B1 (en) Soluble guanylate cyclase activators
EP2365752B1 (en) Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
TWI469983B (zh) 用於治療神經病症之咪唑並［５，１－ｆ］［１，２，４］三類
TWI592398B (zh) 吡啶酮及嗒酮衍生物
CA2890009C (en) Heteroaromatic compounds and their use as dopamine d1 ligands
AU2013343105B2 (en) Heteroaromatic compounds as dopamine D1 ligands
JP2020513403A (ja) 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法
TW200806661A (en) Glucokinase activators
JP2010518014A (ja) キナーゼ阻害剤として有用な２−アミノピリジン誘導体
CN110603254A (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
US9914736B2 (en) TrKA kinase inhibitors, compositions and methods thereof
HK1217482A1 (en) Enzyme modulators and therapies
CN107207467A (zh) 作为parg的抑制剂的2,4‑二氧代‑喹唑啉‑6磺酰胺衍生物
KR20220003173A (ko) 화합물 및 이의 용도
CN101679408A (zh) 作为fgfr抑制剂的双环杂环化合物
JP7621351B2 (ja) Ｇｐｒ５２モジュレーター化合物
KR20210005593A (ko) 화합물 및 이의 용도
CA2946471C (en) Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands
TW201200515A (en) Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors
CN101553232A (zh) 用于治疗增殖性疾病的激酶抑制剂
CN111356695B (zh) 新的三环化合物
EP4587434A1 (en) N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
EP4377304A1 (en) Srpk inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20090520

C20 Patent right or utility model deemed to be abandoned or is abandoned